These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 26043212)

  • 1. Identification of melanoma initiating cells: does CD271 have a future?
    Ballotti R
    Future Oncol; 2015; 11(11):1587-90. PubMed ID: 26043212
    [No Abstract]   [Full Text] [Related]  

  • 2. The nerve growth factor receptor CD271 is crucial to maintain tumorigenicity and stem-like properties of melanoma cells.
    Redmer T; Welte Y; Behrens D; Fichtner I; Przybilla D; Wruck W; Yaspo ML; Lehrach H; Schäfer R; Regenbrecht CR
    PLoS One; 2014; 9(5):e92596. PubMed ID: 24799129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity.
    Boyle SE; Fedele CG; Corbin V; Wybacz E; Szeto P; Lewin J; Young RJ; Wong A; Fuller R; Spillane J; Speakman D; Donahoe S; Pohl M; Gyorki D; Henderson MA; Johnstone RW; Papenfuss AT; Shackleton M
    Cancer Res; 2016 Jul; 76(13):3965-77. PubMed ID: 27325642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stem cell marker CD271 is expressed by vasculogenic mimicry-forming uveal melanoma cells in three-dimensional cultures.
    Valyi-Nagy K; Kormos B; Ali M; Shukla D; Valyi-Nagy T
    Mol Vis; 2012; 18():588-92. PubMed ID: 22419851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD271 is an imperfect marker for melanoma initiating cells.
    Cheli Y; Bonnazi VF; Jacquel A; Allegra M; De Donatis GM; Bahadoran P; Bertolotto C; Ballotti R
    Oncotarget; 2014 Jul; 5(14):5272-83. PubMed ID: 25105565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD271 Down-Regulation Promotes Melanoma Progression and Invasion in Three-Dimensional Models and in Zebrafish.
    Saltari A; Truzzi F; Quadri M; Lotti R; Palazzo E; Grisendi G; Tiso N; Marconi A; Pincelli C
    J Invest Dermatol; 2016 Oct; 136(10):2049-2058. PubMed ID: 27328305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of melanoma stem cell marker CD271 in metastatic melanoma to the brain.
    Guo R; Fierro-Fine A; Goddard L; Russell M; Chen J; Liu CZ; Fung KM; Hassell LA
    Int J Clin Exp Pathol; 2014; 7(12):8947-51. PubMed ID: 25674270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tracking of Melanoma Cell Plasticity by Transcriptional Reporters.
    Vidal A; Redmer T
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD271 defines a stem cell-like population in hypopharyngeal cancer.
    Imai T; Tamai K; Oizumi S; Oyama K; Yamaguchi K; Sato I; Satoh K; Matsuura K; Saijo S; Sugamura K; Tanaka N
    PLoS One; 2013; 8(4):e62002. PubMed ID: 23626764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271.
    Boiko AD; Razorenova OV; van de Rijn M; Swetter SM; Johnson DL; Ly DP; Butler PD; Yang GP; Joshua B; Kaplan MJ; Longaker MT; Weissman IL
    Nature; 2010 Jul; 466(7302):133-7. PubMed ID: 20596026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth.
    Civenni G; Walter A; Kobert N; Mihic-Probst D; Zipser M; Belloni B; Seifert B; Moch H; Dummer R; van den Broek M; Sommer L
    Cancer Res; 2011 Apr; 71(8):3098-109. PubMed ID: 21393506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical CD271 expression correlates with melanoma progress in a case-control study.
    Nielsen PS; Riber-Hansen R; Steiniche T
    Pathology; 2018 Jun; 50(4):402-410. PubMed ID: 29678478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells.
    Knappe N; Novak D; Weina K; Bernhardt M; Reith M; Larribere L; Hölzel M; Tüting T; Gebhardt C; Umansky V; Utikal J
    Stem Cells; 2016 Apr; 34(4):832-46. PubMed ID: 26753613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD271 determines migratory properties of melanoma cells.
    Radke J; Roßner F; Redmer T
    Sci Rep; 2017 Aug; 7(1):9834. PubMed ID: 28852061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy Resistance by Inflammation-Induced Dedifferentiation.
    Mehta A; Kim YJ; Robert L; Tsoi J; Comin-Anduix B; Berent-Maoz B; Cochran AJ; Economou JS; Tumeh PC; Puig-Saus C; Ribas A
    Cancer Discov; 2018 Aug; 8(8):935-943. PubMed ID: 29899062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterising the phenotypic evolution of circulating tumour cells during treatment.
    Tsao SC; Wang J; Wang Y; Behren A; Cebon J; Trau M
    Nat Commun; 2018 Apr; 9(1):1482. PubMed ID: 29662054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma stem cells--are there devils in the detail?
    Shackleton M
    Pigment Cell Melanoma Res; 2010 Oct; 23(5):693-4. PubMed ID: 20704685
    [No Abstract]   [Full Text] [Related]  

  • 18. Melanoma stem cells.
    Roesch A
    J Dtsch Dermatol Ges; 2015 Feb; 13(2):118-24. PubMed ID: 25631128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stem cells and targeted approaches to melanoma cure.
    Murphy GF; Wilson BJ; Girouard SD; Frank NY; Frank MH
    Mol Aspects Med; 2014 Oct; 39():33-49. PubMed ID: 24145241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer stem cells: Invitation to a second round.
    Dirks P
    Nature; 2010 Jul; 466(7302):40-1. PubMed ID: 20596007
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.